CN117915905A - 用于治疗口服利尿剂难治性水肿的皮下制剂和方法 - Google Patents

用于治疗口服利尿剂难治性水肿的皮下制剂和方法 Download PDF

Info

Publication number
CN117915905A
CN117915905A CN202280053609.8A CN202280053609A CN117915905A CN 117915905 A CN117915905 A CN 117915905A CN 202280053609 A CN202280053609 A CN 202280053609A CN 117915905 A CN117915905 A CN 117915905A
Authority
CN
China
Prior art keywords
bumetanide
pharmaceutical composition
subject
aqueous solution
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053609.8A
Other languages
English (en)
Chinese (zh)
Inventor
B·拉哈克里什南
B·埃斯克
W·林
A·X·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resjoy Pharmaceuticals LLC
Original Assignee
Resjoy Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resjoy Pharmaceuticals LLC filed Critical Resjoy Pharmaceuticals LLC
Publication of CN117915905A publication Critical patent/CN117915905A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280053609.8A 2021-06-09 2022-06-09 用于治疗口服利尿剂难治性水肿的皮下制剂和方法 Pending CN117915905A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
US63/208,863 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
CN117915905A true CN117915905A (zh) 2024-04-19

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053609.8A Pending CN117915905A (zh) 2021-06-09 2022-06-09 用于治疗口服利尿剂难治性水肿的皮下制剂和方法

Country Status (10)

Country Link
US (1) US20240285566A1 (https=)
EP (1) EP4351554A4 (https=)
JP (1) JP2024520788A (https=)
KR (1) KR20240042402A (https=)
CN (1) CN117915905A (https=)
AU (1) AU2022289724A1 (https=)
BR (1) BR112023025880A2 (https=)
CA (1) CA3221710A1 (https=)
IL (1) IL309160A (https=)
WO (1) WO2022261344A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7906555B2 (en) * 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20210163406A1 (en) * 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
IL293429A (en) * 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Also Published As

Publication number Publication date
BR112023025880A2 (pt) 2024-02-27
IL309160A (en) 2024-02-01
KR20240042402A (ko) 2024-04-02
CA3221710A1 (en) 2022-12-15
WO2022261344A1 (en) 2022-12-15
EP4351554A4 (en) 2025-05-07
AU2022289724A1 (en) 2024-01-18
JP2024520788A (ja) 2024-05-24
US20240285566A1 (en) 2024-08-29
EP4351554A1 (en) 2024-04-17
WO2022261344A8 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US11357855B2 (en) Liquid formulation
US12558330B2 (en) Methods and compositions for treating edema refractory to oral diuretics
KR102462275B1 (ko) 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
Sintov et al. Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies
CA2707484C (en) Improved formulations and methods for lyophilization and lyophilates provided thereby
KR20020066776A (ko) 인슐린의 경구투여용 제형과 그의 제조방법
KR20190005871A (ko) 안정한 니모디핀 비경구 제제
JP2016533377A (ja) 利尿薬によって誘発される血漿量の変化
US20120040970A1 (en) Intranasal delivery system for dantrolene
ES2380318T3 (es) Formulaciones nanoparticulares de megestrol
CN117915905A (zh) 用于治疗口服利尿剂难治性水肿的皮下制剂和方法
BG64668B1 (bg) Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда
JP2023533129A (ja) 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法
CN101181284A (zh) 注射用伊曲康唑冻干组合物及制备方法
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics
RU2838027C1 (ru) Фармацевтическая композиция, содержащая элемен, способ ее получения и ее применение
US20250170094A1 (en) Anti-influenza virus pharmaceutical formulations
Ichai et al. Sodium disorders
CN120713836A (zh) 一种尼莫地平注射液及其制备方法
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination